What is Vizgen?
Vizgen is dedicated to pioneering the next generation of genomics, providing tools that demonstrate the possibilities of in situ single-cell spatial genomics, setting the standard for the spatial genomics field. These tools are enabling researchers to gain new insight into the biological systems that govern human health and disease with spatial context. The company's MERSCOPE Platform enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and unrivaled detection efficiency at subcellular resolution. MERSCOPE provides transformative insight into a wide range of tissue-scale basic research and translational medicine in oncology, immunology, neuroscience, infectious disease, developmental biology, cell and gene therapy, and is an essential tool for accelerating drug discovery and development.
How much funding has Vizgen raised?
Vizgen has raised a total of $139.7M across 4 funding rounds:
Series A
$14M
Series B
$37M
Series C
$85.2M
Debt
$3.5M
Series A (2020): $14M with participation from Northpond Ventures and ARCH Venture Partners
Series B (2021): $37M led by David Walt, Pura Vida Investments, Tao Capital Management, and ARCH VENTURE PARTNERS
Series C (2022): $85.2M supported by Northpond Ventures, Sofina, Blue Water Life Science Advisors, Tao Capital Management, Novalis LifeSciences, and ARCH Venture Partners
Debt (2025): $3.5M, investors not publicly disclosed
Key Investors in Vizgen
ARCH Venture Partners
ARCH Venture Partners is a leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often co-founding startups with scientists and entrepreneurs.
Sofina
Sofina is a private equity and venture capital firm specializing in direct and fund of funds investments, with a strong focus on digital transformation and healthcare innovation.
Novalis LifeSciences
Novalis LifeSciences is a boutique investment and advisory firm focused on the life science industry, providing direct investments and strategic advisory services for diagnostics and biopharma therapeutics.
What's next for Vizgen?
With the recent influx of capital, Vizgen is well-positioned to expand its commercial footprint and enhance its R&D capabilities. The strategic focus will likely center on broadening the application of the MERSCOPE platform across diverse therapeutic areas, including oncology and immunology, where spatial context is increasingly vital for drug discovery. As the company matures, it will likely prioritize the integration of its technology into clinical workflows, potentially bridging the gap between translational research and diagnostic utility. The continued support from high-profile life science investors suggests a long-term commitment to establishing Vizgen as the definitive standard in spatial biology, ensuring the company remains at the forefront of the rapidly evolving genomics market.
See full Vizgen company page
